High altitude cough (HAC) Respiratory Cough
Conditions
Interventions
Please note that as of 30/07/10 this trial has been extended from 01/10/2010 to 01/10/2011
The study will take place in the Everest base camp (5300 m).
Mountaineers as they ascend to base camp will
Sponsors
University of Oxford (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy men or women 2. Between the ages of 18 and 65 years 3. Have HAC, defined as persistent (greater than 1 day) sometimes paroxysmal cough that disturbs sleep or daily activity or both. The cough may be dry or productive but is not associated with fever, chills, shortness of breath or desaturation less than 75% at Everest Base Camp (EBC) (5300 m).
Exclusion criteria
Exclusion criteria: 1. Individuals with other obvious diagnoses causing cough (e.g., viral or bacterial pneumonia, high altitude pulmonary oedema [HAPE]) 2. Unwillingness to comply with study treatment 3. Lack of informed consent 4. Individuals on beta agonists or steroid inhalers, steroid nasal sprays or oral steroids within the last 2 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of HAC using the modified the Leicester Cough Questionnaire before and after the rotahaler intervention. Measured at day 0, day 7 and day 14 of the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at day 0, day 7 and day 14 of the study: 1. Oxygen saturation 2. Peak flow 3. Pulse 4. Lung auscultation | — |
Countries
Nepal
Outcome results
None listed